Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.

Saved in:
Bibliographic Details
Title: Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.
Authors: Kong, Amanda M.1 (AUTHOR), Lucia, Jacqueline1 (AUTHOR), Christoph, Mary J.2 (AUTHOR), Mordi, Uche2 (AUTHOR), Joseph, Daisha1 (AUTHOR), Askin, Gulce1 (AUTHOR), Yucuma, Daniela3 (AUTHOR), Menezes, Neia Prata2 (AUTHOR), McMahon, Peter2 (AUTHOR), Lim, Travis2 (AUTHOR) travis.lim1@gilead.com
Source: Drugs & Aging. Feb2026, Vol. 43 Issue 2, p175-187. 13p.
Database: Academic Search Ultimate
Description
ISSN:1170229X
DOI:10.1007/s40266-026-01279-9